FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

February 18, 2021 7:00 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

Dial-In InformationLive (U.S./Canada): (877) 658-9081Live (International): (602) 563-8732Confirmation number: 3055327

A replay of the webcast and investor presentation will be available shortly after the call for a period of 30 days. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and use passcode 3055327.

About FibroGen

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). For more information, please visit www.fibrogen.com.

Contacts:FibroGen, Inc.

Investors:Michael Tung, M.D.Corporate Strategy / Investor Relations 1.415.978.1434mtung@fibrogen.com 

Media:Jennifer Harrington +1.610.574.9196Jennifer.Harrington@gcihealth.com 

 

Primary Logo

Source: FibroGen, Inc


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Earnings